Repost from, Sage Journals, February 2006
Cannabinoid Analgesia as a Potential New Therapeutic Option in the Treatment of Chronic Pain
Tammy L Burns:
Tammy L Burns PharmD, at time of writing, Pharmacy Practice Resident, Creighton University Medical Center, Omaha, NE; now, Clinical Pharmacist, Mayo Clinic, Rochester, MN
Joseph R Ineck:
Joseph R Ineck PharmD, Clinical Specialist in Pain Management & Palliative Care; Assistant Professor, Department of Pharmacy Practice, School of Pharmacy and Health Professions, Creighton University
Dr. Ineck, Department of Phamacy Practice, School of Pharmacy and Health Professions, Creighton University, 2500 California Plaza, Omaha, NE 68178-0401, fax 402/449-4879, firstname.lastname@example.org
OBJECTIVE: To review the literature concerning the physiology of the endocannabinoid system, current drug development of cannabinoid agonists, and current clinical research on the use of cannabinoid agonists for analgesia.
DATA SOURCES: Articles were identified through a search of MEDLINE (1966–August 2005) using the key words cannabis, cannabinoid, cannabi*, cannabidiol, nabilone, THC, pain, and analgesia. No search limits were included. Additional references were located through review of the bibliographies of the articles identified.
STUDY SELECTION AND DATA EXTRACTION: Studies of cannabinoid agonists for treatment of pain were selected and were not limited by pain type or etiology. Studies or reviews using animal models of pain were also included. Articles that related to the physiology and pharmacology of the endocannabinoid system were evaluated.
DATA SYNTHESIS: The discovery of cannabinoid receptors and endogenous ligands for these receptors has led to increased drug development of cannabinoid agonists. New cannabimimetic agents have been associated with fewer systemic adverse effects than delta-9-tetrahydrocannabinol, including recent development of cannabis medicinal extracts for sublingual use (approved in Canada), and have had promising results for analgesia in initial human trials. Several synthetic cannabinoids have also been studied in humans, including 2 cannabinoid agonists available on the international market.
CONCLUSIONS: Cannabinoids provide a potential approach to pain management with a novel therapeutic target and mechanism. Chronic pain often requires a polypharmaceutical approach to management, and cannabinoids are a potential addition to the arsenal of treatment options.
© 2006 SAGE Publications
doi: 10.1345/aph.1G217 Ann Pharmacother February 2006 vol. 40 no. 2 251-260
I currently suffer from Chronic Back Pain (23-3/4 years) and tried everything to include a Intrathecial Pain Management Pump “IPMP” which is putting Fentynal (100x more potent then Morphine) into my spine 24hrs a day. One of the main issues with the IPMP is during the filling appointment, it is what’s called a “Pocket Fill” or when the Fentynal or Morphine is injected directly into your abdomen, let me just say this has been my only pocket fill in the 18 years I have been using the IPMP system and “IT IS NOT FUN.”
Don’t get me wrong, the IPMP unit does give me a level of 40%-50% pain relief. It is better then being bed ridden but is it worth the 1/160 (+/-) chances of your day going really bad. The purpose of this post is that my IPMP’s battery is down to about only 15-18 months of power left and I am at the point where I need to make the following decision,
1) Keep the IPMP unit
2) Try CBD and see if it all their saying?
Question to you the blogosphere,
Does anyone reading this used CBD for their chronic back pain (nerve) relief? If so,
What are you results and thoughts regarding CBD for pain control? If you don’t mind me asking?